ATE156121T1 - Histamin-h3-rezeptor-agonisten zur therapeutischen anwendung, pharmazeutische zubereitungen, die an h3-rezeptoren-agonistisch wirken, un die methode ihrer darstellung - Google Patents

Histamin-h3-rezeptor-agonisten zur therapeutischen anwendung, pharmazeutische zubereitungen, die an h3-rezeptoren-agonistisch wirken, un die methode ihrer darstellung

Info

Publication number
ATE156121T1
ATE156121T1 AT91910312T AT91910312T ATE156121T1 AT E156121 T1 ATE156121 T1 AT E156121T1 AT 91910312 T AT91910312 T AT 91910312T AT 91910312 T AT91910312 T AT 91910312T AT E156121 T1 ATE156121 T1 AT E156121T1
Authority
AT
Austria
Prior art keywords
histamine
pct
compounds
receptor agonists
receptor
Prior art date
Application number
AT91910312T
Other languages
English (en)
Inventor
Monique Garbarg
Jean-Michel Arrang
Walter Schunack
Ralph Lipp
Holger Stark
Jeanne-Marie Lecomte
Jean-Charles Schwartz
Original Assignee
Inst Nat Sante Rech Med
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Bioprojet Soc Civ filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE156121T1 publication Critical patent/ATE156121T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT91910312T 1990-05-09 1991-05-10 Histamin-h3-rezeptor-agonisten zur therapeutischen anwendung, pharmazeutische zubereitungen, die an h3-rezeptoren-agonistisch wirken, un die methode ihrer darstellung ATE156121T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9005776A FR2661909B1 (fr) 1990-05-09 1990-05-09 Nouveaux composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation.

Publications (1)

Publication Number Publication Date
ATE156121T1 true ATE156121T1 (de) 1997-08-15

Family

ID=9396429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91910312T ATE156121T1 (de) 1990-05-09 1991-05-10 Histamin-h3-rezeptor-agonisten zur therapeutischen anwendung, pharmazeutische zubereitungen, die an h3-rezeptoren-agonistisch wirken, un die methode ihrer darstellung

Country Status (11)

Country Link
US (1) US5342960A (de)
EP (1) EP0482183B1 (de)
JP (1) JP3094384B2 (de)
AT (1) ATE156121T1 (de)
CA (1) CA2063550C (de)
DE (1) DE69127045T2 (de)
DK (1) DK0482183T3 (de)
ES (1) ES2107464T3 (de)
FR (1) FR2661909B1 (de)
GR (1) GR3024991T3 (de)
WO (1) WO1991017146A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633250A (en) * 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
EP0618905B1 (de) * 1991-12-18 1995-10-04 Schering Corporation Imidazolylalkyl- piperazin und -diazepin derivate als histamin h3 agonisten/antagonisten
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5639775A (en) * 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
EP0633882A1 (de) * 1992-04-01 1995-01-18 The University Of Toledo 4-(4'piperidinyl oder 3'-pyrrolidinyl) substituierte imidazole als h3-rezeptor-antagonisten und ihre therapeutische verwendung
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
JP2000189171A (ja) * 1998-12-25 2000-07-11 Banyu Pharmaceut Co Ltd 新規なグアノシン三リン酸（ｇｔｐ）結合タンパク質共役型のレセプタ―タンパク質
EP1147092A1 (de) 1999-01-18 2001-10-24 Novo Nordisk A/S Substituierte imidazole, ihre herstellung und verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
EP1505074A4 (de) * 2002-04-24 2005-12-21 Banyu Pharma Co Ltd Konstitutiv aktive mutanten eines histamin h3 rezeptors und deren verwendungen
AP2007004161A0 (en) 2005-04-28 2007-10-31 Pfizer Ltd Amino acid derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT71653B (en) * 1979-08-15 1982-01-21 Merck & Co Inc Process for preparing allylsulfoxide enzyme inhibitor
FR2548183B1 (fr) * 1983-07-01 1985-10-31 Synthelabo Diphenylazomethines portant un radical imidazolyle, leur preparation et leur application en therapeutique
NL8501093A (nl) * 1985-04-12 1986-11-03 Stamicarbon Werkwijze voor het racemiseren van een optisch aktief n- benzylideenaminozuuramide.
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
FR2630328B1 (fr) * 1988-04-22 1990-08-24 Inst Nat Sante Rech Med Derive de l'histamine, sa preparation et son application en therapeutique

Also Published As

Publication number Publication date
DE69127045D1 (de) 1997-09-04
FR2661909B1 (fr) 1997-08-14
EP0482183B1 (de) 1997-07-30
CA2063550C (en) 2002-02-26
US5342960A (en) 1994-08-30
DE69127045T2 (de) 1998-03-05
DK0482183T3 (da) 1998-03-09
JPH06501241A (ja) 1994-02-10
GR3024991T3 (en) 1998-01-30
ES2107464T3 (es) 1997-12-01
FR2661909A1 (fr) 1991-11-15
WO1991017146A1 (fr) 1991-11-14
EP0482183A1 (de) 1992-04-29
CA2063550A1 (en) 1991-11-10
JP3094384B2 (ja) 2000-10-03

Similar Documents

Publication Publication Date Title
ATE156121T1 (de) Histamin-h3-rezeptor-agonisten zur therapeutischen anwendung, pharmazeutische zubereitungen, die an h3-rezeptoren-agonistisch wirken, un die methode ihrer darstellung
NZ297879A (en) Ondansetron and polyhydric alcohol (a sweetener) in a liquid acidic oral composition form
MY114698A (en) A process for the isolation of galanthamine
AU2614995A (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
YU38795A (sh) Kortikotropinski otpuštajući faktor antagonisti, postupci za njihovo dobijanje i njihove farmaceutske smese
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
PL319373A1 (en) Method of producing single doses by wet granulation
DE69532580D1 (de) Neue antagonistische verbindungen
FI972434A (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
DE69433012D1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
FI932388A0 (fi) 8-en-19,11b-bryggsteroider, deras framstaellning och farmaceutiska preparat innehaollande dem
DE59607683D1 (de) Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
EP0344980A3 (de) Alpha-adrenergische Rezeptorantagonisten
MX9806292A (es) Formulacion de un inhibidor de la 5alfa-reductasa para su administracion oral, y un procedimiento de preparacion y uso del mismo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time